Results 281 to 290 of about 39,064 (303)

Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.

JAMA dermatology, 2023
Importance Biosimilars have the potential to reduce costs for the management of moderate-to-severe psoriasis compared with originators. However, the extrapolation of evidence enables the approval of a biosimilar for use in indications held by the ...
D. B. Phan, S. Elyoussfi, Michael Stevenson, M. Lunt, R. Warren, Zenas Z N Yiu   +5 more
semanticscholar   +1 more source

Projected US savings from biosimilars, 2021-2025.

American Journal of Managed Care, 2022
OBJECTIVES Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain.
Andrew W Mulcahy, Christine Buttorff, K. Finegold, Zeid El-Kilani, Jon F Oliver, Stephen Murphy, Amber Jessup   +6 more
semanticscholar   +1 more source

Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Inflammatory Bowel Diseases, 2022
BACKGROUND Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator.
A. Tursi, G. Mocci, L. Allegretta, G. Aragona, M. Bianco, R. Colucci, A. Cuomo, N. della Valle, A. Ferronato, G. Forti, F. Gaiani, G. Giorgetti, M. Graziani, K. Lofano, R. Lorenzetti, T. Larussa, A. Penna, R. Pica, G. Pranzo, S. Rodino, A. Scarcelli, C. Zampaletta, G. Bassotti, A. Cazzato, S. Chiri, V. Clemente, A. Cocco, Gianluigi De’ Angelis, L. Donnarumma, R. Faggiani, Camilla Graziosi, M. Le Grazie, F. Luzza, C. Meucci, R. Monterubbianesi, C. Pagnini, P. Perazzo, M. Picchio, R. Sacco, L. Sebkova, M. Serio, D. Napolitano, D. Pugliese, F. Scaldaferri, E. Schiavoni, L. Turchini, A. Armuzzi, W. Elisei, G. Maconi, A. Papa   +49 more
semanticscholar   +1 more source

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

Dermatologic Therapy, 2022
In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa.
G. Roccuzzo, G. Rozzo, L. Burzi, Federica Repetto, P. Dapavo, S. Ribero, P. Quaglino   +6 more
semanticscholar   +1 more source

An Institutional Guide for Formulary Decisions of Biosimilars

Hospital Pharmacy, 2022
Biologics have changed the landscape for the management of many debilitating chronic diseases but account for a significant expenditure of medications globally.
Sherine Ismail, L. A. Abu Esba, M. Khan, Hana Alabdulkarim, Hind Modimagh, C. Yousef   +5 more
semanticscholar   +1 more source

Patients’ Perceptions of Biosimilars: A Systematic Review

BioDrugs, 2023
Qiyou Wu, Zhitao Wang, Xin Wang, Hui Yu, Jing Sun   +4 more
semanticscholar   +1 more source

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Frontiers in Pharmacology, 2020
Evelien Moorkens, Brian Godman, Isabelle Huys   +2 more
exaly  

Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland

International Journal of Clinical Pharmacy, 2021
B. Duggan, Amelia Smith, M. Barry
semanticscholar   +1 more source

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars

Nature Reviews Drug Discovery, 2012
John R Engen
exaly  

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow‐up survey

United European Gastroenterology Journal, 2019
Laurent Peyrin-biroulet, Silvio Danese
exaly